Ysios Capital, a Spain-based specialist life sciences VC firm, has launched ‘InceptionBio’, a new fund focused on biotech company creation and early-stage project development with a target size of €100m (US$115m).
InceptionBio will focus on identifying, developing and building new companies around high-quality science, with a particular focus on Spain. It will primarily invest in technology transfer opportunities and early-stage companies, enabling Ysios to work closely with universities, research centres and scientific entrepreneurs to accelerate the translation of scientific discoveries into new therapies.
“Spain has world-class science and a unique opportunity to translate that science into globally impactful biotech companies, ” said Joan Perelló, managing partner at Ysios Capital who leads the initiative alongside Arturo Urrios, partner.
The fund has already completed a first closing, with participation from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through its SICC Innvierte programme. CDTI-Innvierte’s backing reinforces public-private collaboration in a strategic area for the Spanish biotech ecosystem and will help strengthen the competitiveness of Spain’s R&D system.
A pipeline of investment opportunities that aims to support the creation of at least three new biotech companies in 2026 is under advanced review.
“We see a significant opportunity to identify differentiated scientific assets, translate them into high-potential companies, and attract the talent and capital needed to develop them,” said Urrios. “InceptionBio was created to connect science, entrepreneurship and investment, working closely with both the public and private sectors to accelerate company creation across Europe, with a clear focus on Spain.”
Press release: Ysios Capital launches InceptionBio with a target size of €100 million – Capital-Riesgo.es
